Abstract
The Australian Federal Government’s National Medicines Policy aims to create positive health outcomes for all Australians by providing appropriate access to medicines. Underpinning the policy is the Pharmaceutical Benefits Scheme (PBS), which subsidises the cost of medicines. However, like many healthcare systems around the world, governments are struggling with the challenge of how to manage escalating healthcare expenditure. The landscape is dotted with competing agendas: increased demand for healthcare due to population growth and ageing; patient preferences over treatment options; improved technologies and medicines; the need for pharmaceutical companies to recoup research and manufacturing costs—all have been seen as culprits behind a rising national healthcare bill. Further, spending a dollar on one form of healthcare means not spending a dollar on another. In other words, providing healthcare has an opportunity cost. Increasingly, decision-makers are using economic evaluations as a tool to balance these agenda trade-offs. Only through balance can we ensure that healthcare continues to provide value for money and the system remains sustainable. This chapter explains how the PBS works—its decision-making bodies and processes, how economic evaluation is key to recommending which new medicines are listed on the PBS, and the industry’s perspective on the PBS. The case study focuses on the human papillomavirus (HPV) vaccine to highlight the competing resource demands, business interests, and societal needs that influenced its listing on the PBS. The case study also considers how making the vaccine available through the National Immunisation Programme has contributed to making Australia’s healthcare system more sustainable.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amendment to the National Health Act 1953 Subsection 3(a). Commonwealth Government of Australia
Australian Institute of Health and Welfare (2018) Australia’s health 2018. Australian Institute of Health and Welfare, Canberra, ACT
Bulfone L (2009) High prices for generics in Australia—more competition might help. Austr Health Rev 33:200–214
Cancer Council Australia (2017) HPV vaccine. Cancer Council Australia, Victoria, Australia. Retrieved from http://www.hpvvaccine.org.au/parents/parents-what-is-hpv.aspx
Clarke PM, Fitzgerald EM (2010) Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Med J Aust 192:633–636
Crisp N (2017) What would a sustainable health and care system look like? BMJ 358:1–3
Department of Health (2015) Annual Report 2014–2015. Commonwealth of Australia, Canberra, ACT
Department of Health (2017) The Australian immunisation handbook, 10th edn. Commonwealth of Australia, Canberra, ACT
Department of Health (2018a) National cervical screening program. Department of Health, Canberra, ACT. Retrieved from http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/about-the-new-test
Department of Health (2018b) Price disclosure. Retrieved from http://www.pbs.gov.au/info/industry/pricing/price-disclosure-spd
Department of Health (2018c) Fees, patient contributions and safety net thresholds. Retrieved from http://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee
Department of Health (2019) Historical pharmaceutical benefits scheme expenditure (1948–49 to 2017–18). Retrieved from http://www.pbs.gov.au/info/statistics/expenditure-prescriptions/expenditure-prescriptions-twelve-months-to-30-june-2018
Department of Health and Ageing (2000) National medicines policy. Department of Health and Ageing, Canberra
Dimmock NJ, Easton AJ, Leppard KN (2007) Introduction to modern virology. UK, Blackwell Publishing, Oxford
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford
Frazer I (2016) 2016: 10th anniversary of world’s first HPV vaccine. Australian Cancer Research Foundation (ACRF). Retrieved from https://home.cancerresearch/10th-anniversary-of-worlds-first-hpv-vaccine/
GSK Australia and ViiV Healthcare (2018) The pharmaceutical benefits scheme in Australia: an explainer on system components. GSK Australia
Haas M, Ashton T, Kerstin B, Christiansen T, Conis E, Crivelli L, Kin LM, Lisac M, Macadam M, Schlette S (2009) Drugs, sex, money and power: an HPV vaccine case study. Health Policy 92:288–295
Harris AH, Hill SR, Chin G, Li JJ, Walkom E (2008) The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994–2004. Med Decis Making 28:713–722
Hynd A, Roughead E, Preen D, Glover J, Bulsara M, Semmens J (2008) The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf 17:1091–1099
International Society for Pharmacoeconomics and Outcomes Research (2018) Pharmacoeconomic guidelines around the world. Retrieved from https://www.ispor.org/PEguidelines/
Jonsson E, Banta D (1999) Management of health technologies: an international view. BMJ British Med J 319:1293
Krelle R (2005) CSL, Merck strengthen bid to be first to market with HPV vaccine. Retrieved from https://www.labonline.com.au/content/life-scientist/news/csl-merck-strengthen-bid-to-be-first-to-market-with-hpv-vaccine-1142801499
Lavelle P (2006) Saving money on medicines. ABC. Retrieved from http://www.abc.net.au/health/consumerguides/stories/2006/04/17/1837734.htm
Lofgren H (2007) Reshaping Australian drug policy: the dilemmas of generic medicines policy. Australian and New Zealand Health Policy 4:11
McNeil C (2006) Who invented the VLP cervical cancer vaccines? J Natl Cancer Inst 98:433
Medicines Australia (2017) Strengthening the PBS: agreement with medicines Australia on behalf of the innovative medicines sector. Canberra, MA. Retrieved from https://medicinesaustralia.com.au/wp-content/uploads/sites/52/2017/05/09-May-2017-Summary-Document-Strenghtening-the-PBS.pdf
Moss E (2017) Ten years on, Professor Ian Frazer recalls ‘lucky’ discovery of cervical cancer vaccine. ABC. Retrieved from http://www.abc.net.au/news/2017-03-25/ian-frazer-recalls-lucky-discovery-of-cervical-cancer-vaccine/8385872
National Health Act (1953) Commonwealth Government of Australia. Retrieved from https://www.legislation.gov.au/Details/C2018C00308
National Cancer Institute (2018) Human papillomavirus vaccines (HPV). NCI. Retrieved from https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet
Parkinson B (2013) Pharmaceutical policy in Australia. CHERE Working Paper 2013/01. UTS, Sydney, Australia, CHERE, University of Technology, Sydney
Parliament of Australia (2016) The pharmaceutical benefits scheme: a quick guide. Commonwealth of Australia, Canberra, ACT, 7 Apr 2016
Pharmaceutical Benefits Advisory Committee (2007) Public summary document for quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine, injection, 0.5 mL, Gardasil. Commonwealth of Australia, Canberra, ACT
Pharmaceutical Benefits Advisory Committee (2011) Public summary document for quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine, injection, 0.5 mL, Gardasil. Commonwealth of Australia, Canberra, ACT
Pharmaceutical Benefits Advisory Committee (2016) Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). Retrieved from https://pbac.pbs.gov.au/
Pharmaceutical Benefits Advisory Committee (2017) Public summary document: Human papillomavirus 9-valent vaccine: injection 0.5 mL, pre-filled Syringe Gardasil® 9. Commonwealth of Australia, Canberra, ACT
Pharmaceutical Benefits Advisory Committee December (2008) Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Department of Health and Ageing, Canberra, ACT
PWC (2015) Challenges and change: a report on the Australian pharmaceutical industry. PWC, Sydney
Productivity Commission (2005) Impacts of advances in medical technology in Australia, research report. Melbourne, PC
Raftery JP (2008) Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust 188:26
Sloan C (1995) A history of the Pharmaceutical Benefits Scheme 1947–1992. Commonwealth Department of Human Services and Health, Canberra
Sweeny K (2013) The impact of further PBS reforms: report to medicines Australia. Victoria University
Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, Mcnamee K, Garefalakis M, Garland SM (2012) Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 206:1645–1651
Viney R, Haywood P, De Abreu Lourenco R (2017) Explainer: how is the price of medicine decided in Australia? The conversation. Retrieved from https://theconversation.com/explainer-how-is-the-price-of-medicine-decided-in-australia-83633
WHO (2011) Health technology assessment of medical devices. World Health Organisation. Retrieved from http://apps.who.int/medicinedocs/en/d/Js21560en/
WHO (2018) WHO essential medicines list (EML). World Health Organisation. Retrieved from http://www.who.int/medicines/publications/essentialmedicines/en/
Zhou J, Sun XY, Stenzel DJ, Frazer IH (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185:251–257
Zur Hausen H (1976) Condylomata acuminata and human genital cancer. Can Res 36:794
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Epp, J., Parkinson, B., Hawse, S. (2020). Health System Sustainability: The Pharmaceutical Benefits Scheme in Australia. In: Wood, L., Tan, L., Breyer, Y., Hawse, S. (eds) Industry and Higher Education. Springer, Singapore. https://doi.org/10.1007/978-981-15-0874-5_2
Download citation
DOI: https://doi.org/10.1007/978-981-15-0874-5_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-0873-8
Online ISBN: 978-981-15-0874-5
eBook Packages: EducationEducation (R0)